KfW acquires minority interest in CureVac AG on behalf of the Federal Government

On behalf of the German Federal Government, KfW has acquired shares in CureVac AG for an amount of approximately EUR 300 million. CureVac is a German biopharmaceutical company which has specialised on research and development in the field of "mRNA"-based medicines. The Tübingen-based company with its around 450 employees is currently developing an mRNA-based vaccine against COVID-19, as well as other viral infections, such as rabies and an mRNA-based product candidate for the treatment of different forms of cancer.

KfW carries out this transaction on behalf of the German Federal Government ("mandated transaction"). Opportunities and risks arising from this transaction lie with the Federal Government. KfW does not assume any entrepreneurial or strategic responsibility. The shareholder rights are exercised at the instruction of the German Federal Government.